How Analysts Feel About InVivo Therapeutics Holdings Corp. (NVIV) After Achieving 1 Year Low?

April 17, 2018 - By Stephen Andrade

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Logo

The stock of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) hit a new 52-week low and has $7.82 target or 7.00 % below today’s $8.41 share price. The 5 months bearish chart indicates high risk for the $320.03M company. The 1-year low was reported on Apr, 17 by Barchart.com. If the $7.82 price target is reached, the company will be worth $22.40 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 1.17% or $0.0975 during the last trading session, reaching $8.41. About 22,557 shares traded. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has declined 87.02% since April 17, 2017 and is downtrending. It has underperformed by 98.57% the S&P500.

Analysts await InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) to report earnings on May, 3. They expect $-0.17 earnings per share, up 15.00 % or $0.03 from last year’s $-0.2 per share. After $-0.13 actual earnings per share reported by InVivo Therapeutics Holdings Corp. for the previous quarter, Wall Street now forecasts 30.77 % negative EPS growth.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company has market cap of $320.03 million. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: